In a market flooded with AI buzzwords, Weave is solving one of drug development's most critical bottlenecks: regulatory workflows that determine how quickly life-changing therapies reach patients.
Today, we're proud to announce our $20M Series A, led by
@USVP_ , with participation from
@iendeavors,
@magneticvc,
@trailmixvc , @CharacterVC, and Serrado Capital.
This isn't just about technology—it's about impact:
✅ Accelerating regulatory timelines by 50%+
✅ Expanding across the full therapeutic lifecycle (IND to NDA to post-market)
✅ Scaling globally to serve drug developers worldwide
What sets us apart? We're AI-native by design, not by rebranding. Our platform delivers speed, accuracy, and compliance—powered by AI, validated by human expertise.
The future of regulatory workflows is here. And it's built on substance, not hype.
👉Read the full announcement:
businesswire.com/news/home/2…
#WeaveBio #SeriesA #DrugDevelopment #RegulatoryInnovation #AIinPharma #Biotech #LifeSciences